Aditxt, Evofem enter second amendment to plan of merger

Aditx (ADTX) and Evofem Biosciences (EVFM) announced they have entered into the second amendment to the amended and restated agreement and plan of merger, under which Aditxt intends to acquire Evofem. Under the second amendment, the parties have extended the dates by which Aditxt shall complete the remaining $3M in funding to Evofem through the purchase of 3,000 shares of Evofem’s F-1 Preferred Stock. Aditxt will provide $1.5M of financing by September 30 and an additional $1.5M by October 31. Both companies continue to work collaboratively to align strategic priorities and expect to close the transaction in the fourth quarter.